Detalles de la búsqueda
1.
Safety and activity of alectinib against systemic disease and brain metastases in patients with crizotinib-resistant ALK-rearranged non-small-cell lung cancer (AF-002JG): results from the dose-finding portion of a phase 1/2 study.
Lancet Oncol
; 15(10): 1119-28, 2014 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-25153538
Resultados
1 -
1
de 1
1
Próxima >
>>